Study of Amimaitosai plus steroids for gut graft-versus-host disease
Treatments studied
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have a blood cancer that is typically treated with a stem cell transplant.
- You have received a stem cell transplant from a donor.
- You have gastrointestinal symptoms that are caused by graft-versus-host disease.
- Your liver and kidney function must be within certain limits.
- You must not have uncontrolled infections or severe psychiatric disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
This trial tests whether a special probiotic made from the patient's own gut bacteria and their donor's can help fix gut problems caused by a complication called graft-versus-host disease (aGVHD) after a stem cell transplant. It might help patients who are over 50 and scheduled for a specific type of transplant.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This trial tests if adding vitamin C to standard steroid treatment helps control gut graft-versus-host disease (GVHD) after a stem cell transplant. It aims to reduce inflammation and improve symptoms in patients starting their first treatment for GI GVHD.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Hear when a new Acute Gastrointestinal Graft-versus-host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.